Synpromics, UCL ally to aim gene therapies at blood-based diseases – FierceBiotech
FierceBiotech |
Synpromics, UCL ally to aim gene therapies at blood-based diseases
FierceBiotech Synpromics has entered into another gene therapy collaboration with UCL. This time around the aim is to apply Synpromics' synthetic promoter expertise to the development of gene therapies against diseases affecting blood production. Working with Adrian … Synpromics Announces New Partnership with UCL to Develop … Gene therapy developer Synpromics signs collaboration deal … Collaboration formed for development of novel gene therapies for … |
